CORT Overview
Upcoming Projects (CORT)
-
Discussing Corcept’s Lead Drug Candidate, Relacorilant + Nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
Ticker: CORT
Execute By: Dec 06, 2024
Executed Projects (CORT)
-
A Second View: Discussing Corcept Therapeutics' Relacorilant Program, following Phase 3 GRACE Topline Results
Ticker: CORT
Executed On: Jun 11, 2024 at 11:00 AM EDT -
Discussing Corcept Therapeutics' Relacorilant Program, following Phase 3 GRACE Topline Results
Ticker: CORT
Executed On: Jun 11, 2024 at 10:10 AM EDT -
Discussing treatment options for Cushing Syndrome and the potential of relacorilant from Corcept Therapeutics
Ticker: CORT
Executed On: Mar 07, 2024 at 01:00 PM EST -
A Second Discussion With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.
Tickers: CORT, TEVA
Executed On: Feb 02, 2024 at 04:00 PM EST -
Speaking With a Payor Expert on the Impact of a Closed Loop Distribution System with a Hub on the Entrance of a Generic in Ultra Orphan Diseases.
Tickers: CORT, TEVA
Executed On: Jan 30, 2024 at 04:30 PM EST
Expired Projects (CORT)
Upcoming & Overdue Catalysts (CORT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CORT)
-
Phase 1/2 of Corcept's(CORT) Relacorilant plus Abraxane in Solid tumors (cancer) to be presented at ASCO
Ticker: CORT
Occurred on: Jun 03, 2019 -
Corcept Therapeutics' (CORT) Relacorilant Phase 3 trial expected to start in second half of 2018
Ticker: CORT
Occurred on: Nov 19, 2018 -
Phase 1/2 trial of Corcept's (CORT) relacorilant plus abraxane in treating patients with solid tumors data to be realeased late 2018
Ticker: CORT
Occurred on: Jun 04, 2018 -
Corcept Therapeutics (CORT) Presents Interim Results of Relacorilant Phase 2 Trial
Ticker: CORT
Occurred on: Feb 22, 2018 -
Corcept's (CORT) Phase 1 Study of Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer Completed
Ticker: CORT
Occurred on: Dec 20, 2017 -
Recruitment underway in Phase 2 trial of CORT125134 to treat patients with Cushing’s syndrome
Ticker: CORT
Occurred on: Aug 02, 2016 -
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program
Ticker: CORT
Occurred on: Jun 02, 2016
Strategic Initiatives (CORT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
